Infliximab is used for the research of autoimmune diseases, chronic inflammatory disorders, and diabetic neuropathy; it ameliorates TNF-α-induced insulin resistance in vitro by restoring the insulin signaling pathway via PTP1B inhibition; in vivo, it suppresses elevated serum TNF-α levels and improves electrophysiological and biochemical deficits in diabetic mice for at least 4 weeks.